OptimAbs is a unique range of assays that can measure both serum biologics levels and antibodies to these biologics. It provides valuable information to help guide your treatment decisions for patients treated by biologics.
OptimAbs assays are available for eight biologic drugs used to treat patients with inflammatory bowel disease (IBD):
- OptimAbs Adalimumab (Humira®)
- OptimAbs Certolizumab pegol (Cimzia®)
- OptimAbs Golimumab (Simponi®)
- OptimAbs Infliximab (Remicade®)
- OptimAbs Infliximab-dyyb (Inflectra®)
- OptimAbs Infliximab-abda (Renflexis®)
- OptimAbs Ustekinumab (Stelara®)
- OptimAbs Vedolizumab (Entyvio®)